



## Announcement Summary

---

**Entity name**

KAZIA THERAPEUTICS LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

Wednesday April 8, 2020

**The Proposed issue is:**

A placement or other type of issue

**Total number of +securities proposed to be issued for a placement or other type of issue**

<b>ASX +Security Code</b>	<b>+Security Description</b>	<b>Maximum Number of +securities to be issued</b>
KZA	ORDINARY FULLY PAID	18,041,667

**Proposed +issue date**

Thursday April 16, 2020

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

---

**1.1 Name of +Entity**

KAZIA THERAPEUTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

**1.2 Registered Number Type**

ABN

**Registration Number**

37063259754

**1.3 ASX issuer code**

KZA

**1.4 The announcement is**

New announcement

**1.5 Date of this announcement**

Wednesday April 8, 2020

**1.6 The Proposed issue is:**

A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

**7A.1 - Are any of the following approvals required for the placement or other type of issue?**

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

No

Part 7B - Issue details

**Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?**

Existing class

**Will the proposed issue of this +security include an offer of attaching +securities?**

No

Details of +securities proposed to be issued

**ASX +Security Code and Description**

KZA : ORDINARY FULLY PAID

**Maximum Number of +securities proposed to be issued**

18,041,667

**Purpose of the issue**

The funds will be used as follows:

- \* to progress the paxalisib Phase II clinical trial and to complete analysis of the ongoing Phase I study of Cantrixil;
- \* to continue to provide contributory funding towards four other trials;
- \* to contribute to set-up of our planned pivotal study in paxalisib (GBM AGILE); and
- \* working capital for the Company.

**Offer price details for retail security holders**

**In what currency is the cash consideration being paid?**

AUD - Australian Dollar

**What is the issue price per +security?**

AUD 0.40000



**Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?**

Yes

#### **Oversubscription & Scale back details**

**May a scale back be applied to this event?**

No

---

#### Part 7C - Timetable

---

##### **7C.1 Proposed +issue date**

Thursday April 16, 2020

#### Part 7D - Listing Rule requirements

---

**7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?**

No

**7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

Yes

**7D.1b ( i ) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?**

18,041,667 shares are to be issued under the enhanced LR 7.1 capacity announced by ASX on 31 March 2020.

**7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?**

No

**7D.2 Is a party referred to in listing rule 10.11.1 participating in the proposed issue?**

No

**7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?**

No

**7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?**

No

#### Part 7E - Fees and expenses

---

**7E.1 Will there be a lead manager or broker to the proposed issue?**

Yes

---



**7E.1a Who is the lead manager/broker?**

Bell Potter

**7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?**

Commission is based on a percentage of the amounts raised and is estimated to be approximately 6%.

**7E.2 Is the proposed issue to be underwritten?**

No

**7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue**

Part 7F - Further Information

---

**7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?**

No

**7F.2 Any other information the entity wishes to provide about the proposed issue**